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Abstract Hyponatremia (Na 135 mmol/l) is the most fre-
quent electrolyte disorder in clinical practice, and the syn-
drome of inappropriate antidiuretic hormone secretion
(SIADH) is the commonest cause of hyponatremia in cancer
patients. Correcting hyponatremia in these patients can reduce
morbidity and mortality, increase the response to anti-cancer
agents, and help reduce hospital length of stay and costs.
Tolvaptan is an oral medication used to treat SIADH-related
hyponatremia patients that needs to be initiated at hospital so
patients can have their serum sodium monitored. If tolvaptan
could be initiated in hospital day care units (DCUs),
performing the same tests, hospitalization could be avoided,
quality of life improved, and costs reduced. This is the first
publication where a panel of oncologists are sharing their ex-
perience and making some recommendations with the use of
tolvaptan to treat SIADH-related hyponatremia in DCU after
collecting and examining 35 clinical cases with these type of
patients. The conclusion from this retrospective observational
analysis is that the use of tolvaptan in DCU is safe and effec-
tive in the therapeutic management of SIADH-related
hyponatremia.
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Introduction
Hyponatremia (Na <135 mmol/l) is the most common elec-
trolyte disorder in clinical practice, affecting around 15–28 %
of hospitalized patients [1] and occurring in up to 44 % in
certain cancers, such as small cell lung cancer (SCLC) [2].
The most frequent cause of hyponatremia in the hospital set-
ting is the syndrome of inappropriate antidiuretic hormone
secretion (SIADH) [3]. SIADH is also the commonest cause
of hyponatremia in cancer patients, representing around 30 %
of the total [4].
Hyponatremia is associated with high morbidity and mor-
tality [5, 6] and poorer response to anti-cancer agents [2]. It
causes longer hospital length of stay and increases medical
costs [6–8].
Tolvaptan is an oral treatment indicated for adult patients
with hyponatremia secondary to SIADH [9]. This is the first
publication about the use of tolvaptan in hospital day care unit
(DCU).
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Definition, classification, and diagnosis of hyponatremia
Hyponatremia is defined as a serum sodium concentration
below 135 mmol/l. It is considered Bmild^ if values are be-
tween 130 and 135 mmol/l, Bmoderate^ if between 120 and
129 mmol/l, and Bsevere^ if below 120 mmol/l. As for the
symptoms, it can be classified as mild, moderate, or severe
according to their intensity. Hyponatremia is considered
Bacute^ if developed in less than 48 h or Bchronic^ if devel-
oped over a longer period of time [10]. Also, it can be classi-
fied as iso-osmolar, hyperosmolar, and hypotonic or hypo-
osmolar [10]. Hypotonic hyponatremia is most frequently en-
countered in clinical practice (60 % of all cases), especially in
cancer patients, and the commonest cause of hypotonic
hyponatremia with euvolemia is SIADH [10].
The differential diagnosis of hyponatremia can be per-
formed with an exhaustive anamnesis, physical examination
assessing the extracellular fluid volume status, and simple
blood and urine laboratory tests [2, 11].
SIADH-related hyponatremia
SIADH is commonly caused by cancers, certain medications,
central nervous system (CNS) disorders, pulmonary diseases,
or other causes (AIDS, idiopathic, etc.) [12].
In cancer patients, SIADH is a paraneoplastic syndrome
associated with a wide range of tumors but about 75 % of all
cases are encountered in SCLC [13]. SIADH may be a result
of ectopic arginine vasopressin (AVP) production by tumor
cells or a result of stimulation of AVP secretion or potentiation
of AVP effects by some anti-cancer drugs as well as by other
factors like diarrhea or vomiting (Table 1) [2, 11].
Before turning the diagnosis of SIADH, other clinical en-
tities need to be excluded like hypothyroidism, hypopituita-
rism, severe emotional or physical stress, and medications that
stimulate AVP release [14]. Several consensus documents
have established the diagnosis criteria of SIADH in cancer
patients (Table 2) [10].
Clinical consequences of hyponatremia due to SIADH
Hypotonic hyponatremia causes cerebral oedema, intracranial
hypertension, and risk of brain injury [15, 16]. Patients with
mild hyponatremia are traditionally asymptomatic. At serum
concentrations between 125 and 130 mmol/l, anorexia, nau-
sea, vomiting, and abdominal pain may develop. As serum
sodium concentration falls, agitation, confusion, hallucina-
tions, incontinence, and other neurological symptoms pre-
dominate. Hyponatremia below 115 mmol/l may induce seri-
ous neurological squeals and constitutes a medical emergency
[17].
Treatment of SIADH-related hyponatremia in cancer
patients
Untreated acute hyponatremia can cause substantial mor-
bidity and mortality as a result of osmotically induced ce-
rebral edema, and excessively rapid correction can cause
severe neurologic impairment and death as a result of os-
motic demyelination [16]. Some recently published guide-
lines have reviewed the management of SIADH in cancer
patients (Fig. 1) [10, 18].
Table 1 The causes of SIADH in cancer patients
Cancer Drugs known to cause hyponatremia by affecting AVP
production/action
Lung diseases
SCLC Mechanism: increased hypothalamic AVP production Infections: pneumonia (bacterial or viral),
tuberculosisGastrointestinal cancer
Pancreas adenocarcinoma Anti-cancer agents: Vinca alkaloids, platinum compounds,
alkylating agents, and othersHematological cancers
Sarcomas Palliative medications: opioid analgesics, antidepressants,
antipsychotics, and antiepileptics
Respiratory acute failure
CNS (primary and metastatic cancer) Mechanism: potentiation AVP actions
Prostate adenocarcinoma Anti-cancer agents: alkylating agents
Urothelial cancer Palliative medications: nonsteroidal anti-inflammatory




AVP arginine vasopressin, CNS central nervous system, SCLC small cell lung cancer
Table adapted from Alcázar et al., FMC Oncología, March 2013, and Castillo et al., The Oncologist, 2012; 17:756–65
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Treating SIADH in hospital DCU
Hyponatremia is more common in hospitalized patients
than in ambulatory individuals [19] and is independently
associated with a higher risk in death, with increased
length of stay and cost of care for hospitalized patients
[5–8]. Mild hyponatremia occurs in 15 to 22 % of those
patients and in approximately 7 % of ambulatory patients;
moderate hyponatremia occurs in 1 to 7 % of hospitalized
patients [12]. Oncology DCU allow patients to receive
specialized care without needing to be hospitalized.
Tolvaptan is an oral medication that in spite of being safe,
like stated in the summary of product characteristics, it
needs to be initiated at hospital so patients can have their
serum sodium monitored [9]. If tolvaptan could be initiated
in hospital DCU, hospitalization could be avoided, quality
of life improved, and costs reduced.
Rationale for the use of tolvaptan in hospital DCU
Clinical and economic impact of hyponatremia
in hospitalized cancer patients
Several studies and a meta-analysis, with hospitalized on-
cology patients, show the negative prognostic impact of
the presence of hyponatremia in survival, clinical out-
comes, and quality of life, and on the other hand, economic
data can be extrapolated from studies on non-cancer pa-
tients regarding prolongation of hospital stay and increased
hospital costs for this reason.
Table 2 SIADH diagnostic criteria
Serum Na <135 mmol/l
Plasma osmolarity <275 mOsm/kg
Urine osmolarity >100 mOsm/kg
Hypotonic hyponatremia with clinical euvolemia
Absence of signs of hypovolemia (normal eye pressure values, normal venous
pressure, no orthostatism)
Absence of signs of hypervolemia (ascites, edemas)
Urinary Na >40 mmol/l (in the presence of dietary sodium)
No hypothyroidism, no adrenal insufficiency (hypocortisolism) or renal failure
No recent diuretic intake
Absence of physiological stimuli for AVP secretion (recent surgery,
severe pain AVP secretion stimulating drugs…)
Table adapted from De las Peñas R et al. Clin Trans Oncol. 2014
AVP arginine vasopressin
Fig. 1 Treatment algorithm for hyponatremia in cancer patients. De las Peñas et al. Clin Transl Oncol. 2014; 16:1051–9
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Clinical impact on survival, chemotherapy outcomes/patients
prognosis, and ECOG score
Hyponatremia is associated with an increase in hospital
mortality Several studies in oncology patients showed direct
alterations on survival in relation with hyponatremia [11,
20–22]. A low serum sodium level could affect negatively
the performance status and the quality of life of cancer pa-
tients, and may delay time-critical treatments such as chemo-
therapy [22]. Even mild hyponatremias have been associated
with an increase in mortality in hospitalized patients [23]. In
3357 cancer patients hospitalized at the MDAnderson Cancer
Center in 2006 for 3 months, hyponatremia was associated
with worst survival during 90 days [24]. An analysis of all
adult patients discharged from an academic medical center,
during a 7-year period showed that mortality was significantly
associated with a serum Na+ <138 mmol/l and Na+
>142 mmol/l [25].
Patients with hyponatremia who do not fully normalize
the serum sodium value have a worse prognosis than those
who normalize it Hyponatremia was associated with poorer
prognosis in a study with 402 patients treated with
carboplatin-etoposide. Interestingly, patients with ectopic pro-
duction of atrial natriuretic peptide (ANP) are reported to re-
spond poorly to water restriction, and lack of response to
water restriction within few days is suggested as screening test
for ectopic production of ANP in hyponatremia SCLC pa-
tients. The treatment of hyponatremia at the study institution
has predominantly been the prescription of water restriction,
and in the series only 25 % of the patients with hyponatremia
(<130 mmol/l) had fully normalized serum sodium to values
above 135 mmol/l at the time of the second cycle of chemo-
therapy 3–4 weeks after the first cycle [20].
Hyponatremia is associated with worsening of serum so-
dium levels during hospitalization In the Anderson Cancer
Center study, hyponatremia was noted in 47 % of the patients
(23 % at admission and 24 % was acquired during hospitali-
zation) [24]. Data from an academic medical center in Canada
reveal that hyponatremia worsening after admission was ob-
served in 6 % of hospitalizations associated with community-
acquired hyponatremia, while 38 % developed during hospi-
talization [25].
Satisfaction with care in cancer patients treated at hospital
DCU is high A study that evaluated the satisfaction with care
in cancer patients treated at hospital DCU showed that satis-
faction with care in this setting is high and correlation between
satisfaction with care and quality of life indicated that these
two concerns are complementary [26].
The ECOGperformance status score at admission shows a
negative correlation with the sodium status A study that
checked the effects of hyponatremia among patients with lung
carcinoma on their Eastern Cooperative Oncology Group
(ECOG) performance showed that the ECOG score at admis-
sion shows a negative correlation with the serum sodium sta-
tus measured on admission among all the patients. The ECOG
score correlated with the duration of the patient survival and
the response to treatment, as well as their quality of life and
co-morbidity. This study concludes that hyponatremia may
influence the ECOG performance status score, which serves
as an important factor in the prognosis of lung cancer [27].
Economic impact in hospital costs and hospital length of stay
and complications
Hyponatremia increases hospital costsA retrospective anal-
ysis that evaluated the impact of varying levels of
hyponatremia at admission on cost of care in adult hospital-
ized patients showed median costs of $16,606 for moderate-
to-severe hyponatremia cases, $14,266 for mild-to-moderate,
and $13,066 for normal admissions (P<0.001). Based on an
annual admission rate at that institution of approximately 55,
000, it was estimated that patients admitted with hyponatremia
were associated with an additional $2.15 million in hospital
costs and over 3400 additional bed days [28].
Data from the Integrated HealthCare Information Services
National Managed Care Benchmark Database showed that
hyponatremia was associated with 99 % higher 6-months costs,
and also associated with 108 % higher 1-year medical costs. It
was estimated that hyponatremia increased direct medical costs
at 6 and 12 months (41. 2 and 45.7 %, respectively) [29].
An analysis performed to estimate the annual cost of
hyponatremia in the USA showed that 55–63 % of
hyponatremia patients are initially treated as inpatients, 25 %
are initially treated in the emergency room, and 13–20 % are
treated solely in the office setting. The direct costs of treating
hyponatremia in the USA on an annual basis were estimated
to range from $1.6 to $3.6 billion. Hospitalization costs (in-
cluding readmissions) accounted for approximately 70 % of
the total cost of illness [30].
Hyponatremia in cancer patients at admission is associat-
ed with longer length of stay and hospital complications
The Anderson Cancer Center study showed that the length of
stay of patients with hyponatremia was significantly higher
than for those with normal sodium levels (10.2+10.2 vs.
5.6+5.0 days; P<0.01), and for those mild/moderate
hyponatremia cases, the length of stay was also higher (9.9
and 13.0+14.1 vs. 5.6+5.0 days) [24].
On the other hand, patients with more severe hyponatremia
were also more likely to be admitted to the intensive care unit
during the hospital stay (moderate-to-severe hyponatremia,
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32 %; mild-to-moderate hyponatremia, 26 %; normal, 22 %;
P<0.001) [28].
The extrapolation of these data to studies with cancer patients
confronts us with the fact that almost 50 % of hospitalized pa-
tients have hyponatremia, as we have seen, and its presence
prolongs the duration of hospitalization in 2–5 days [28]. A
recent study with 105 consecutive cancer patients showed a sta-
tistically significant correlation between the length of stay and
the detection of hyponatremia both at admission (P=0.0009) and
during hospitalization (P=0.0001). In this study, and according
to this length of stay, a patient with moderate hyponatremia cost
128 % more than a normonatremic patient [21].
Advantages for the use of tolvaptan in DCU
DCU are specialized places where patients can have all the
controls needed after the first administration of tolvaptan so,
taking into account the mentioned clinical and economic impact
of hyponatremia in hospitalized cancer patients, we can presume
that the ambulatory early correction with tolvaptan in DCU can:
& Facilitate the administration of chemotherapy cycles in a
timely manner, which could probably improve the tumor
disease and increase patient’s survival.
& Ease the prompt correction of serum sodium levels, for a
quick start of chemotherapy, which would presumably
have a positive impact in the patients’ prognosis.
& Minimize the risk of hyponatremia getting worst during
hospitalization, when possible.
& Make the patient’s treatment compatible with their daily ac-
tivities and allow these patients to be closer to their families.
& Have a positive impact in the quality of life of oncology
patients with hyponatremia.
& Reduce costs originated from hospitalization as well as
decrease the emergencies which are the usual route of
entry for these patients to hospital.
& Prevent hospital admission, in selected patients, with the
associated hospitalization risks like prolonged length of stay
and admission to intensive care units helping reduce hospital
costs as well as health complications for the patient.
Management and recommendations for the use
of tolvaptan to treat SIADH in hospital DCU
Clinical experience based on clinical cases with the use
of tolvaptan in hospital DCU
Active treatment of SIADH-related hyponatremia must be
started as soon as possible to avoid delays in the patients’
oncologic treatment [31], and also because in a significant
number of cases, the hyponatremia origin is paraneoplastic
and the tumor treatment itself becomes a key factor for the
correction of the natremia [11].
While in severe, very symptomatic situations, hypertonic
saline solution is considered the standard of care [10, 11, 31]
in those cases of moderate hyponatremia, where a controlled
increase of the natremia is desired, the first line treatment
would be hydric restriction or tolpalvan administration [11].
In particular, hydric restriction may not be possible in the
oncologic population because these patients require high hy-
dration for their intravenous treatment administration.
Moreover, the natremia correction rate is often inadequate
and has a low treatment adherence [11]. Tolvaptan meets the
requirements of rapidity, efficacy, safety, and adherence, so it
can be considered a good treatment choice, especially in those
patients in whom the treatment of the malignancy that is caus-
ing the SIADH requires an immediate start of chemotherapy
that cannot be administered without adequate hydration vol-
umes [11, 13] or in malnourished patients, for whom liquid
restriction would worsen their nutritional state [31].
Tolvaptan is usually initiated in hospital due to the need for
a dose titration phase with close monitoring of serum sodium
and volume status 4–6 h after its administration [9]. However,
since this type of control can be done at DCU, these units
could help avoid hospitalization in some selected cancer pa-
tients with hyponatremia, with all the advantages described
previously.
To evaluate this retrospectively, a series of 35 clinical cases
were collected from cancer patients receiving treatment with
tolvaptan in 3 hospital DCU in Spain [Hospital Provincial de
Castellón, Castellón (from September 2011 to May 2014);
Hospital Doce de Octubre, Madrid (from March 2013 to
September 2014); and Hospital Virgen de la Macarena,
Sevilla (from August 2011 to December 2014)] (Table 3).
In all cases, it was suspected a paraneoplastic-related
SIADH, and 63 % of the patients underwent treatments that
could exacerbate the hyponatremia (18 with opioids, 5 with
diuretics, and 3 with antidepressants). Furthermore, 74 % of
these patients showed symptomatic hyponatremia and 11 of
them showed at least two characteristic symptoms of this elec-
trolyte disorder. The most predominant symptomatology was
neurologic. Three patients with severe symptoms were initial-
ly treated with hypertonic saline solution. After having con-
trolled the acute initial situation in these patients, they
underwent hydric restriction together with other eight patients
that did not require this initial treatment. Afterwards, when the
criteria for natremia correction were not achieved, tolvaptan
was used. In the remaining patients that were not candidates
for hydric restriction, tolvaptan treatment was initiated direct-
ly, following the general guidelines of the treatment algorithm
described in Fig. 1. When tolvaptan was used, no significant
changes in vital signs described in Fig. 1 were observed.
The results showed that 12 of the 13 patients monitored
after 4–6 h of treatment initiation improved their serum
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sodium levels without an overcorrection, with two patients
needing a dose escalation to 30 mg. After 24 h, 2 of the 35
patients had no serum sodium correction, 1 patient a slight
over correction (13 mmol/l), and all the rest of patients had
correct corrections of their serum sodium. The time to restore
their natremia was 1–4 days for 18 patients, more than 4 days
(maximumwas 29) for 13 patients, a partial response (defined
as an improvement of sodium levels without reaching normal
values) for 3 patients, and no response (described as no
sodium improvement) for 1 patient. Twenty-four patients
stopped tolvaptan without any adjustment period when they
needed it, 2 had a gradual dose reduction, and 9 reduced the
dose by having it on alternate days until withdrawn. Adverse
effects were reported in 17 patients, mainly thirst (9 mild and
3 moderate) and polyuria (6 mild and 4 moderate). Only four
mild cases of dry mouth and two mild cases of hepatic
enzymes elevation (both of them with liver metastases)
were reported. No cases of osmotic demyelization or other
adverse events were reported. Common Terminology Criteria
for Adverse Events V4.0 (CTCAE scale) was used to grade
the severity of each adverse events. Twenty patients could
receive chemotherapy after their serum sodium correction (9
immediately after, 1 after 3 h, 1 after 5 h, 5 after 24 h, and 4
after 48 h), and 1 of them also underwent radiotherapy after
the correction. There was no morbidity nor mortality
associated to the use of tolvaptan throughout the treatment.
This data reinforces the drug safety described in previous
publications [1, 9, 31]. General mortality fluctuated between
4 and 68 weeks since the beginning of hyponatremia
treatment (n=16). However, this data is of limited value due
to the sample being small and heterogeneous (tumors at
different stages of the disease; the tumor is often diagnosed
long before the hyponatremia, mortality is thus related to the
evolution of the disease itself).
Table 3 Patients and disease characteristics at admission
Patients, n (%) 35
- Male 16 (46)
- Female 19 (54)
Median age, years (range) 66 (42–85)
Type of cancer, n° of patients
- SCLC 15
- NSCLC 7





- Multiple myeloma 1
- Colon 1
- Oesophagus 1




- Unknown primary site 1
Vital signs prior tolvaptan treatment, median (range)
- Weight (kg) 67 (52–80) (from n= 34)
- Heart rate (bpm) 85 (66–100) (from n=
18)
- Blood pressure (mmHg) 128 (155–110) – 72 (85–
60) (from n= 17)
Median natremia prior tolvaptan treatment
initiation, mmol/L, (range)
125 (117–130)
Type of hyponatremia, n° of patients (%)
- Mild (130–135 mmol/L) 2 (6)
- Moderate (120–129 mmol/L) 31 (88)
- Severe (Below 120 mmol/L) 2 (6)
Patient symptomatic, n° of patients (%) 26 (74)
- Headache 13 (50)
- Asthenia 6 (23)
- Weakness 4 (15)
- Dizziness 4 (15)
- Confusion 3 (12)
- Unsteady gait 3 (12)
- Disorientation 2 (8)
- Fall 1 (4)
- Sleepiness 1 (4)
Treatments before Tolvaptan, n° of patients
(%)
11 (31)
- Fluids restriction 11 (31)
- Hypertonic infusion 3 (9)
- No prior treatment 24 (69)
Results (Tolvaptan)
Patients monitored after treatment initiation, n° of patients (%)
- After 4-6h 13 (37)
- After 24 hours 35 (100)
Table 3 (continued)
Patients, n (%) 35
Days to restore the natremia, n° of patients (%)
- 1–4 days 18 (51)
- More than 4 days 13 (37)
- Partial response 3 (9)
- No response 1 (3)
Adverse events reported, n° of patients Mild Moderate Severe
- Thirst 9 3 0
- Polyuria 6 4 0
- Dry mouth 4 0 0
- Hepatic enzymes elevation 2 0 0
- Others 0 0 0
NSCLC no small cell lung cancer, SCLC small cell lung cancer
504 Support Care Cancer (2016) 24:499–507
Based on the findings from these clinical cases, all
hyponatremia patients were correctly treated in the DCU, with
no serious adverse effects from the medication. They all
started chemotherapy in no more than 48 h. Subsequently,
the treatment with tolvaptan might have led to an improve-
ment of the ECOG-performance status. In addition, all pa-
tients benefited from the effective management of SIADH
by receiving the hyponatremia treatment in the same place
they received their chemotherapy and also by being able to
go home instead of going through the inconveniences and
risks that can arise with hospitalization. Our conclusion is that
hyponatremia can be treated in hospital DCU as long as proper
monitoring of the serum levels can be performed.
Despite the limitations of retrospective observational stud-
ies, the positive results of these cases support the hypothesis
that tolvaptan can be used effectively and safely in hospital
DCU. There is no other similar published data so our experi-
ence and recommendations can be a good reference for other
professionals in the field who may want to benefit from
treating their patients with tolvaptan as outpatients instead of
in hospital.
Recommendations for the use of tolvaptan in hospital
DCU
Based on the previous information, some minimum recom-
mendations are proposed.
Patient selection
& The most suited patients for this protocol are those with
moderate hyponatremia (120–129 mmol/l) with
mild/moderate symptoms, currently on anti-cancer active
or palliative treatment (provided that the correction of
hyponatremia is part of their established treatment
strategy).
& Patients at higher risk of demyelination syndromes (those
with hypoxia, alcoholism, or malnutrition) should be
avoided since they would need closer management [9].
Patients must not present any contraindications for the
use of tolvaptan like hypersensitivity to the active sub-
stance/excipients, anuria, volume depletion, hypovolemic
hyponatremia, and hypernatremia, patients who cannot
perceive thirst and pregnancy or breast feeding [9].
& Patients must be able to stay at the hospital within 6 h for
an analytical control and then return again 24 h after treat-
ment initiation for further controls. In addition, they
should live at less than 1-h distance from hospital in case
of emergency as well as have good family support. This
protocol can only be carried out in DCU with a minimum
of 12 h continued attention so patients can have a control
6 h after treatment initiation.
& Patients/their relatives will be informed about the possible
side effects of the treatment with tolvaptan and asked to
return to hospital immediately if the patient experiences
any of them.
Treatment dose
& After establishing the diagnosis and verifying the selection
criteria are met, treatment with tolvaptan can be initiated in
DCU at a dose of 15 mg once daily. The dose may be
increased to a maximum of 60 mg once daily as tolerated
to achieve the desired level of serum sodium [9]. Patients
may drink fluids freely after treatment initiation [9].
Analytical controls after the first tolvaptan dose
& An analytical control (for serum sodium and volume sta-
tus) is recommended no later than 6 h after. If there is no
over rapid serum sodium correction, the patient can be
sent home and have another control 24 h after treatment
initiation. If it shows worsening of the patient’s condition
or serum sodium correction exceeds 6 mmol/l within 6 h,
the patient should be hospitalized for closer monitoring
and administration of hypertonic fluids.
& If serum sodium increases ≥12 mmol/l within 24 h or
≥18 mmol/l within 48 h or there is a hypernatremia
>145 mmol/l, tolvaptan treatment needs to be interrupted
or discontinued followed by administration of hypotonic
fluid [9]. If it increases <136+≤5 mmol/l within 24 h, the
tolvaptan dose should be increased.
& Further controls will be done after 3–10 days depending
on patients’ overall condition and serum sodium correc-
tion as well as circumstances like the date of their next
appointment.
Treatment duration and withdrawal recommendation
& Tolvaptan should continue until the underlying disease is
adequately treated or until hyponatremia is no longer a
clinical problem [10]. According to the results of our se-
ries, natremia was normalized in 51 % of patients in the
first 4 days, increasing to 88 % of them within 29 days of
treatment with tolvaptan.
& For patients on a 15-mg dose, tolvaptan can be withdrawn
abruptly or reduced gradually/taken on alternate days, as
clinically indicated. If patients are on higher doses, i.e.,
30 mg, gradual dose reduction is preferred until the dose
reaches 15 mg and then it can be withdrawn abruptly or
gradually as mentioned before.
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With regard to cancer:
& For SCLC (highly chemo sensible): If there is an improve-
ment of the hyponatremia after 7 days, to reduce the dose
to one tablet every 48 h or 7.5 mg every 24 h; if there is no
improvement, to keep the same dose. If there is improve-
ment after 14 days, stop the treatment. Have an additional
control after 21 days.
& For head and neck cancer: Since the patient is on radio-
therapy, to have him/her controlled every week to consider
stopping tolvaptan. If the cancer is disseminated, the man-
agement would be similar to that of SCLC.
& For lymphomas: To use a similar management than for
SCLC since it is highly chemo sensible.
& Other tumors: It will depend on the treatment outcomes
and the treatment schedules.
& In palliative care: Always keep tolvaptan if there is an
improvement in the symptoms.
When to start chemotherapy
Start chemotherapy as soon as possible, depending as well on
other factors like the tumor type or the date of the week.
Suggested algorithm for the use of tolvaptan in DCU
The main mentioned recommendations for the use of
tolvaptan in patients with moderate hyponatremias (120–
129 mmol/l) candidate or not candidate for chemotherapy in
hospital DCU have been established based on the described
clinical experience and publications. The aim of these recom-
mendations is to guide other professionals in the field to con-
sider treating their moderate SIADH-related hyponatremia on-
cology patients in hospital DCU (Fig. 2).
To summarize, it is suggested to administer 15 mg of
tolvaptan at hospital DCU with a control of the natremia 6 h
after. If the control shows worsening or over correction of
serum sodium levels, the patient should be hospitalized for
closer monitoring. If the patient shows improvement, another
control should be performed 18 h after. If the control shows
improvement, chemotherapy can be started after 24 h in those
patients that are candidate for it and withdrawal of tolvaptan
will be considered as previously described. In those not can-
didate to chemotherapy, tolvaptan therapy should be contin-
ued until symptoms improve. In all cases, another control of
serum sodium levels should be performed 3–10 days after.
Conclusions
Our retrospective study confirms that tolvaptan can be admin-
istered ambulatory in hospital DCU in those patients with a
moderate hyponatremia (120–139 mmol/l) with mild-to-
moderate symptoms, currently on anti-cancer active or pallia-
tive treatment.
The correction of hyponatremia in cancer patients can help
reduce hospital stays, potentially resulting in savings, improve
Fig. 2 Recommendations for
treating hyponatremia in cancer
patients in hospital day care units
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hyponatremia-related symptoms, as well as increase patients
overall quality of life and survival.
The use of tolvaptan has proven to be safe and effective in
the therapeutic management of SIADH-related hyponatremia
in hospital DCU.
Conflict of interest This publication was funded by Otsuka
Pharmaceutical Spain, without involving any legal commitment on the
results. None of the authors who participated in this paper work or have
worked in Otsuka. All authors have collaborated in the conception,
drafting, review, and approval of the manuscript submitted, and agreed
to allow the journal to review their data if requested.
Open Access This article is distributed under the terms of the Creative
Commons Attribution-NonCommercial 4.0 International License (http://
creativecommons.org/licenses/by-nc/4.0/), which permits any noncom-
mercial use, distribution, and reproduction in any medium, provided
you give appropriate credit to the original author(s) and the source, pro-
vide a link to the Creative Commons license, and indicate if changes were
made.
References
1. Verbalis JG, Adler S, Schrier RW, for the SALT Investigators et al
(2011) Efficacy and safety of oral tolvaptan therapy in patients with
the syndrome of inappropriate antidiuretic hormone secretion. Eur J
Endocrinol 164:725–732
2. Alcázar R, Puerta M (2013) SIADH: Pathophysiology, classifica-
tion and diagnosis in the hospitalized patient. FMC: Oncología 8:
supl 1
3. Runkle I, Villabona C, Navarro A et al (2014) Tratamiento de la
hiponatremia secundaria al syndrome de secreción inadecuada de la
hormona antidiurética: algoritmo multidisciplinar. Nefrol 4:439–
450
4. Sørensen JB, Andersen MK, Hansen HH (1995) Syndrome of in-
appropriate secretion of antidiuretic hormone (SIADH) in malig-
nant disease. J Intern Med 238:97–110
5. Gill G, Huda B, Boyd A et al (2006) Characteristics and mortality
of severe hyponatraemia: a hospital based study. Clin Endocrinol
65:246–249
6. Sherlock M, O’Sullivan E, Agha A et al (2006) The incidence and
pathophysiology of hyponatraemia after subarachnoid haemor-
rhage. Clin Endocrinol 64:250–254
7. Sherlock M, O’Sullivan E, Agha A et al (2009) Incidence and
pathophysiology of severe hyponatraemia in neurosurgical patients.
Postgrad Med J 85:171–175
8. Shea AM, Hammill BG, Curtis LH et al (2008) Medical costs of
abnormal serum sodium levels. J A Soc Nephrol 19:764–770
9. Samsca (2014) Summary of product characteristics
10. De las Peñas R, Escobar Y, Henao F et al (2014) SEOM guidelines
on hydroelectrolitic disorders. Clin Transl Oncol. doi:10.1007/
s12094-014-1234-2
11. Castillo JJ, Vicent M, Justice E (2012) Diagnosis and management
of hyponatremia in cancer patients. Oncologist 17:756–765
12. Ellison DH, Berl T (2007) The syndrome of inappropriate
antidiuresis. N Engl J Med 356:2064–2072
13. De las Peñas R (2013) Syndrome of inappropriate antidiuretic hor-
mone secretion in the hospitalized oncologic patient. FMC:
Oncología 8: supl 1
14. Schrier RW, Bansal S (2008) Diagnosis and management of
hyponatremia in acute illness. Curr Opin Crit Care 14:627–634
15. Adrogue HJ, Madias NE (2000) Hyponatremia. N Eng J Med 342:
1581–1589
16. Verbalis JG, Goldsmith SR, Greenberg A et al (2013) Diagnosis,
evaluation, and treatment of hyponatremia: expert panel recommen-
dations. Am J Med 126:S1–S42
17. Hannon MJ, Thompson CJ (2010) The syndrome of inappropriate
antidiuretic hormone: prevalence, causes and consequences. Eur J
Endocrinol 162:S5–S12
18. Grohé C, et al. Hyponatraemia-SIADH in lung cancer diagnostic
and treatment algorithms. Crit Rev Oncol Hematol. 2015 Apr 23.
doi: 10.1016/j.critrevonc.2015.04.005
19. Gankam-Kengne F, Ayers C, Khera A et al (2013) Mild
hyponatremia is associated with an increased risk of death in an
ambulatory setting. Kid Int 83:700–706
20. Hansen O, Sorensen P, Hansen KH (2010) The occurrence of
hyponatremia in SCLC and the influence on prognosis. A retro-
spective study of 453 patients treated in a single institution in a
10-year period. Lung Cancer 68:111–114
21. Berardi R, Caramanti M, Castagnani M et al. (2015) Hyponatremia
is a predictor of hospital length and cost of stay and outcome in
cancer patients. Support Care Cancer. Mar 5
22. Berardi R, Caramanti M, Fiordoliva I et al (2015) Hyponatraemia is
a predictor of clinical outcome for malignant pleural mesothelioma.
Support Care Cancer 23:621–626
23. Waikar SS, Mount DB, Curhan GC et al (2009) Mortality after
hospitalization with mild, moderate, and severe hyponatremia.
Am J Med 122:857–865
24. Doshi SM, Shah P, Lei X et al (2012) Hyponatremia in hospitalized
cancer patients and its impact on clinical outcomes. Am J Kidney
Dis 59:222–228
25. Wald R, Jaber BL, Price LL et al (2010) Impact of hospital-
associated hyponatremia on selected outcomes. Arch Intern Med
170:294–302
26. Arraras JI, Illarramendi JJ, Viudez A et al (2013) Determinants of
patient satisfaction with care in a Spanish oncology day hospital
and its relationship with quality of life. Psycho-Oncology 22:2454–
2461
27. Sengupta A, Banerjee SN, Biswas NM et al (2013) The incidence
of hyponatraemia and its effect on the ECOG performance status
among lung cancer patients. J Clin Diagn Res 7:1678–1682
28. Callahan MA (2009) Economic impact of hyponatremia in hospi-
talized patients: a retrospective cohort study. Postgrad Med 121:
186–191
29. Sheea AM, Hammill BG, Curtis LH et al (2008) Medical costs of
abnormal serum sodium levels. J Am Soc Nephrol 19:764–770
30. Boscoe A, Paramore C, Verbalis JG et al (2006) Cost of illness of
hyponatremia in the United States. Effect Resour All 4:10
31. Runkle I, Gómez-Hoyos E, Cuesta-Hernández M et al (2015)
Hyponatraemia in older patients: a clinical and practical approach.
Rev Clin Gerontol 25:31–52
Support Care Cancer (2016) 24:499–507 507
